| 英文别名 |
Lisinopril;(S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline dihydrate;Lisinopril Dihydrate;(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate;(S)-Lisinopril;Bis(2,4-dinitrophenyl)carbonate;Lisinopril (dihydrate);Lisinopril Hydrate;MK-521;1-[Nα-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline Dihydrate;(S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate;MK-521 dihydrate;L-Proline, 1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-, dihydrate, (S)- (ZCI);L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-, dihydrate (9CI);Zestril (TN);LISINOPRIL COMPONENT OF ZESTORETIC;AC-6226;Prinivil (TN);LISINOPRIL DIHYDRATE [MI];SR-01000801314-3;F20515;Lisinopril Dihydrate; N2-[(1S)-1-Carboxy-3-phenylpropyl]-L-lysyl-L-proline dihydrate; (S)-1-[N2-(1-Carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate;Tox21_110798_1;CHEBI:6503;KS-1078;AKOS015950799;Q47495698;LISINOPRIL COMPONENT OF PRINZIDE;Lisinopril for system suitability A, European Pharmacopoeia (EP) Reference Standard;LISINOPRIL DIHYDRATE [WHO-DD];83915-83-7;HMS3712N04;BL164629;Lisinopril, United States Pharmacopeia (USP) Reference Standard;NSC 758151;Lisinopril dihydrate, European Pharmacopoeia (EP) Reference Standard;L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-, hydrate (1:2);HMS1568N04;Tox21_110798;HY-18206A;(S)-1-(N(sup 2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline dihydrate;L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-, dihydrate, (S)-;D00362;CHEMBL419213;LISINOPRIL HYDRATE [JAN];Ranolip;LISINOPRIL [ORANGE BOOK];SCHEMBL542591;Lisinopril hydrate (JP17);CAS-83915-83-7;(S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline dihydrate;UNII-E7199S1YWR;LISINOPRIL [USP IMPURITY];NSC 751176;LISINOPRIL DIHYDRATE [EP MONOGRAPH];N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline dihydrate;LISINOPRIL [USAN];DTXCID0025600;DTXSID2045600;Lisinopril (USP);S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate;lisinopril-dihydrat;L-Proline, 1-(N(sup 2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-, dihydrate, (S)-;(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid dihydrate;(S)-1-((S)-6-Amino-2-(((S)-1-carboxy-3-phenylpropyl)amino)hexanoyl)pyrrolidine-2-carboxylicaciddihydrate;MFCD01698825;NCGC00179623-04;MK-521 (dihydrate);NCGC00017141-01;SR-01000801314;PRINZIDE COMPONENT LISINOPRIL;Lisinopril, >=98% (HPLC);E7199S1YWR;CCG-220301;EN300-19652794;Lisinopril for peak identification, European Pharmacopoeia (EP) Reference Standard;(S)-1-((S)-6-Amino-2-(((S)-1-carboxy-3-phenylpropyl)amino)hexanoyl)pyrrolidine-2-carboxylic acid dihydrate;1-(N(sup 2)-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline dihydrate;Prestwick_613;Lisinopril [USAN:USP:INN:BAN:JAN];LISINOPRIL [USP-RS];Lisinopril, Pharmaceutical Secondary Standard; Certified Reference Material;LISINOPRIL [HSDB];1ST10889W;(S)-Lisinopril Dihydrate;LISINOPR... |
微信公众号
客服
C1%3dNN2C%3dCC%3dCC2%3dC1)
(F)(F)F.%5bK%2b%5d)
